These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16079485)

  • 41. Is antifungal susceptibility testing useful in guiding fluconazole therapy?
    Ghannoum MA
    Clin Infect Dis; 1996 May; 22 Suppl 2():S161-5. PubMed ID: 8722845
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species.
    Thompson GR; Wiederhold NP; Sutton DA; Fothergill A; Patterson TF
    J Antimicrob Chemother; 2009 Jul; 64(1):79-83. PubMed ID: 19406849
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Allylamine type xanthone antimycotics.
    Salmoiraghi I; Rossi M; Valenti P; Da Re P
    Arch Pharm (Weinheim); 1998 Jun; 331(6):225-7. PubMed ID: 9713256
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fluconazole and amphotericin B antifungal susceptibility testing by National Committee for Clinical Laboratory Standards broth macrodilution method compared with E-test and semiautomated broth microdilution test.
    Rodríguez-Tudela JL; Martinez-Suarez JV
    J Clin Microbiol; 1997 Jan; 35(1):336-7. PubMed ID: 8968944
    [No Abstract]   [Full Text] [Related]  

  • 45. Synthesis and SAR studies of biaryloxy-substituted triazoles as antifungal agents.
    Liu P; Zhu S; Li P; Xie W; Jin Y; Sun Q; Wu Q; Sun P; Zhang Y; Yang X; Jiang Y; Zhang D
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3261-5. PubMed ID: 18467095
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro antifungal activity of fluconazole and voriconazole against non-Candida yeasts and yeast-like fungi clinical isolates.
    Mandras N; Roana J; Scalas D; Fucale G; Allizond V; Banche G; Barbui A; Li Vigni N; Newell VA; Cuffini AM; Tullio V
    New Microbiol; 2015 Oct; 38(4):583-7. PubMed ID: 26485018
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Susceptibility of Mexican isolates of yeasts and moulds to amphotericin B and triazole antifungals.
    Arredondo-García JL; Amábile-Cuevas CF;
    J Infect Dev Ctries; 2009 Jun; 3(5):398-401. PubMed ID: 19759511
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antifungal susceptibility of Cryptococcus neoformans isolates in HIV-infected patients to fluconazole, itraconazole and voriconazole in Spain: 1994-1996 and 1997-2005.
    Aller AI; Claro R; Castro C; Serrano C; Colom MF; Martín-Mazuelos E
    Chemotherapy; 2007; 53(4):300-5. PubMed ID: 17496416
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro response of cutaneous mycosis fungal agents to the most widely used systemic antifungals in dermatology.
    Almeida LM; Souza EA; Bianchin DB; Svidzinski TI
    An Bras Dermatol; 2009 Jul; 84(3):249-55. PubMed ID: 19668938
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Butenafine and superficial mycoses: current status.
    Singal A
    Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):999-1005. PubMed ID: 18624686
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi.
    Capilla J; Ortoneda M; Pastor FJ; Guarro J
    Antimicrob Agents Chemother; 2001 Sep; 45(9):2635-7. PubMed ID: 11502542
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity.
    Gupta AK; Kohli Y
    Br J Dermatol; 2003 Aug; 149(2):296-305. PubMed ID: 12932235
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of butenafine hydrochloride, a new benzylamine derivative, on experimental dermatophytosis in guinea pigs.
    Arika T; Yokoo M; Hase T; Maeda T; Amemiya K; Yamaguchi H
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2250-3. PubMed ID: 2073116
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The antifungal agent butenafine manifests anti-inflammatory activity in vivo.
    Nahm WK; Orengo I; Rosen T
    J Am Acad Dermatol; 1999 Aug; 41(2 Pt 1):203-6. PubMed ID: 10426889
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-Trichophyton mentagrophytes activity and percutaneous permeation of butenafine in guinea pigs.
    Arika T; Hase T; Yokoo M
    Antimicrob Agents Chemother; 1993 Feb; 37(2):363-5. PubMed ID: 8452371
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Topical treatment with butenafine significantly lowers relapse rate in an interdigital tinea pedis model in guinea pigs.
    Arika T; Yokoo M; Yamaguchi H
    Antimicrob Agents Chemother; 1992 Nov; 36(11):2523-5. PubMed ID: 1489197
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro and in vivo antifungal activities of D0870, a new triazole agent.
    Yamada H; Tsuda T; Watanabe T; Ohashi M; Murakami K; Mochizuki H
    Antimicrob Agents Chemother; 1993 Nov; 37(11):2412-7. PubMed ID: 8285626
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro activity of Syn-2869, a novel triazole agent, against emerging and less common mold pathogens.
    Johnson EM; Szekely A; Warnock DW
    Antimicrob Agents Chemother; 1999 May; 43(5):1260-3. PubMed ID: 10223947
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Colony size can be used to determine the MIC of fluconazole for pathogenic yeasts.
    Xu J; Vilgalys R; Mitchell TG
    J Clin Microbiol; 1998 Aug; 36(8):2383-5. PubMed ID: 9666032
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antifungal Susceptibility of Yeasts and Filamentous Fungi by CLSI Broth Microdilution Testing.
    Wiederhold NP
    Methods Mol Biol; 2023; 2658():3-16. PubMed ID: 37024691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.